Skip to main content

Table 1 WST-1 proliferation assay for BT474 cells treated with atRA and trastuzumab

From: Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations

 

Fraction affected

 

Dose

atRA

Trastuzumab

atRA + Tzmab

Combination index

0.2

0.17 ± 0.052

0.26 ± 0.009

0.56 ± 0.021

0.19 ± 0.057

0.4

0.28 ± 0.056

0.51 ± 0.006

0.79 ± 0.037

0.01 ± 0.003

0.6

0.33 ± 0.058

0.58 ± 0.012

0.83 ± 0.049

0.01 ± 0.007

1

0.46 ± 0.046

0.62 ± 0.026

0.86 ± 0.042

0.01 ± 0.005

5

0.52 ± 0.061

0.64 ± 0.023

0.85 ± 0.052

0.07 ± 0.046

10

0.55 ± 0.058

0.66 ± 0.030

0.87 ± 0.048

0.10 ± 0.067

  1. Doses of all-trans retinoic acid (atRA) and trastuzumab (Tzmab) in μM and μg/ml, respectively. Each value is the mean of three independent experiments (with eight replicate wells for each treatment) ± standard error.